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Abstract
Ageing is a complex process characterised by a systemic and progressive deterioration
of biological functions. As ageing is associated with an increased prevalence of age-
related chronic disorders, understanding its underlying molecular mechanisms can pave
the way for therapeutic interventions and managing complications. Animal models such
as mice are commonly used in ageing research as they have a shorter lifespan in compar-
ison to humans and are also genetically close to humans. To assess the translatability of
mouse ageing to human ageing, the urinary proteome in 89 wild-type (C57BL/6) mice
aged between 8–96 weeks was investigated using capillary electrophoresis coupled to
mass spectrometry (CE-MS). Using age as a continuous variable, 295 peptides signifi-
cantly correlated with age in mice were identified. To investigate the relevance of using
mouse models in human ageing studies, a comparison was performed with a previous
correlation analysis using 1227 healthy subjects. In mice and humans, a decrease in
urinary excretion of fibrillar collagens and an increase of uromodulin fragments was
observed with advanced age. Of the 295 peptides correlating with age, 49 had a strong
homology to the respective human age-related peptides. These ortholog peptides includ-
ing several collagen (N = 44) and uromodulin (N = 5) fragments were used to generate an
ageing classifier that was able to discriminate the age among both wild-type mice and
healthy subjects. Additionally, the ageing classifier depicted that telomerase knock-out
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mice were older than their chronological age. Hence, with a focus on ortholog urinary pep-
tides mouse ageing can be translated to human ageing.
Introduction
During a lifetime, a number of molecular and cellular insults accumulate and lead to ageing
[1]. Ageing is therefore a complex process characterised by a systemic and progressive deterio-
ration of biological functions, leading to impaired tissue function thus increasing the likeli-
hood of death. The burden caused by age-related diseases is prominent and prone to increase
over the years. As life expectancy increases, improving health in the elderly population will be
pivotal in dealing with subsequent enormous socio-economic challenges as a consequence of
this improved longevity [2]. There is therefore an urgency to develop intervention strategies
that will improve management of co-morbidities associated with ageing. Management of com-
plications associated with ageing can firstly be accomplished by understanding molecular
mechanisms associated with healthy ageing.
In ageing research, human studies are rare due to limiting factors mainly pertaining to the
challenge in obtaining tissue samples from apparently healthy subjects [3]. As a result, animal
models including mouse models have mostly been used due to obvious factors including
shorter life span and the ease of obtaining samples in comparison to humans. A major concern
of using animal models is the ability (or the lack thereof) to translate results to humans [4]. We
have previously reported the benefit of using urinary proteome analysis in the screening of
suitable animal models for human diseases [5,6]
In the present study our aim was to investigate if findings in ageing research using mouse
models can be translated to humans using urinary proteome (naturally occurring peptides of
less than 20 kDa) analysis. The use of urinary proteome analysis allows obtainment, in a non-
invasive manner, of information on ageing. We have previously shown this in a number of
studies which included over 1200 healthy individuals [7,8]. Comparison of human and mouse
age-related urinary proteomes should provide unique insight in the translatability of mouse
models of ageing.
Materials and methods
Mice
Mice urine samples were obtained from wild-type C57BL/6 strains (N = 89). These mice
included 4 weeks (N = 13), 12 weeks (N = 15), 48 weeks (N = 28), 61 weeks (N = 5), 84 weeks
(N = 13) and 96 weeks (N = 15) old mice that were purchased from Janvier Labs, France. Addi-
tionally, 61 weeks old telomerase knock-out (Terc-/-) mice samples (N = 5) were originally gen-
erated by injecting mTR -/- WW6 ES cells to C57BL/6 recipients and were maintained since
their generation in 1997 on this C57BL/6 background by in-house breeding [9,10]. All animal
experiments were conducted in accordance with the German Law for the welfare of animals
and were approved by the committee from the “Regierungspra¨sidium Freiburg” (approval
number: 35–9185.81/G-11/51).
Humans
To compare mouse ageing with human ageing, we have used the 1227 healthy subjects previ-
ously described in a human ageing study [7]. For the definition and validation of an ageing
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support vector machine (SVM) classifier (see Results), a training set of 50 subjects was estab-
lished by randomly selecting young and old healthy subjects within this cohort of 1227 healthy
subjects. For the definition of the SVM classifier young healthy subjects were considered to be
between 20–39 years (N = 25) whereas older subjects were considered over 60 years (N = 25).
An independent test set was also randomly selected to validate the SVM classifier and it com-
prised of young (20–39; N = 20), mature (40–59; N = 20) and old healthy subjects (60 and
over; N = 20). The study was performed in accordance with the ethical principles in the Decla-
ration of Helsinki and Good Clinical Practice. All datasets were derived from previous studies
and were anonymised. The study was approved by the local ethics committee (approval num-
ber: 3185–2016).
Sample preparation and proteome analysis
The proteomic analysis based on capillary electrophoresis coupled to mass spectrometry
(CE-MS) for human urine samples has already been published [7]. For mouse proteomic anal-
ysis, a 150 μl aliquot of mice urine was thawed immediately before use and diluted with 150 μl
of 2 M urea, 10 mM NH4OH containing 0.02% SDS. To remove higher molecular mass pro-
teins, such as albumin and immunoglobulin G, the sample was ultra-filtered using Centrisart
ultracentrifugation filter devices (20 kDa MWCO; Sartorius, Goettingen, Germany) until
filtrate was obtained. This filtrate was then applied onto a PD-10 desalting column (GE
Healthcare, Uppsala, Sweden) equilibrated in 0.01% NH4OH in HPLC-grade in H2O (Roth,
Germany) to decrease matrix effects by removing urea, electrolytes, salts, and to enrich poly-
peptides present. Finally, all samples were lyophilised, stored at 4˚C, and suspended in HPLC-
grade H2O shortly before capillary electrophoresis coupled to mass spectrometry (CE-MS)
analyses, as described [7].
CE-MS analyses were performed using a P/ACE MDQ capillary electrophoresis system
(Beckman Coulter, Fullerton, USA) on-line coupled to a microTOF MS (Bruker Daltonics,
Bremen, Germany) as described previously [11,12]. The ESI sprayer (Agilent Technologies,
Palo Alto, CA, USA) was grounded, and the ion spray interface potential was set between –4
and –4.5 kV. Data acquisition and MS acquisition methods were automatically controlled by
the CE via contact-close-relays. Spectra were accumulated every 3 s, over a range of m/z 350 to
3000. Accuracy, precision, selectivity, sensitivity, reproducibility, and stability of the CE-MS
measurements were demonstrated elsewhere [11].
Peptide sequencing
For sequencing, processed urine samples were separated on a Dionex Ultimate 3000 RSLS
nano flow system (Dionex, Camberly UK). A 5 ml sample was loaded onto a Dionex 5 mm
C18 nano trap column at a flow rate of 5 ml/min. Elution was performed on an Acclaim Pep-
Map 75 mm C18 nano column over 100 min. The sample was ionised in positive ion mode
using a Proxeon nano spray ESI source (Thermo, Fisher Hemel UK) and analysed in an Orbi-
trap Velos FTMS (Thermo Finnigan, Bremen, Germany). The MS was operated in data-
dependent mode to switch between MS and MS/MS acquisition and parent ions were frag-
mented by (high-) energy collision-induced dissociation and also electron transfer dissocia-
tion. Data files were searched against Mus musculus entries in the Swiss-Prot database with
Proteome Discoverer version 1.2 (Thermo Fisher Scientific, Bremen) with SEQUEST spectral
algorithm. No fixed modification and oxidation of methionine as variable modifications were
selected. Mass error windows of 10 ppm for MS and 0.05 Da (HCD; high resolution) or 0.5 Da
(CID, ETD; low resolution) for MS/MS were allowed. For further validation of obtained pep-
tide identification, the strict correlation between peptide charge at pH 2 and CE-migration
Proteomic analysis in mouse ageing
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time was utilised to minimise false-positive identification rates [13]. Calculated CE migration
time of the sequence candidate based on its peptide sequence (number of basic amino acids)
was compared to the experimental migration time. Peptides were accepted only if they had a
mass deviation below ± 80 ppm and a CE-migration time deviations below ± 2 min. Only
sequenced peptides were considered for further investigation.
Data processing
Mass spectral peaks representing identical molecules at different charge states were deconvo-
luted into single masses using MosaiquesVisu software [14]. Only signals with z>1 observed
in a minimum of three consecutive spectra with a signal-to-noise ratio of at least four were
considered. CE-MS data were calibrated using 150 reference mass data points and 452 refer-
ence migration time data points by locally weighted regression. For normalisation of analyti-
cal and urine dilution variances, signal intensities were normalised relative to 29 internal
standard peptides [15]. The obtained peak lists characterise each peptide by its molecular
mass [Da], normalised CE migration time [min] and normalised signal intensity. All
detected peptides were deposited, matched, and annotated in a Microsoft SQL database
allowing further statistical analysis [16]. For clustering, peptides in different samples were
considered identical if mass deviation was <50 ppm for small (<4,000 Da) or 75 ppm for
larger peptides. Acceptable migration time deviation was, < ± 1 minutes for 19 min, gradu-
ally increasing to, < ± 2.5 min at 50 min. The mass spectrometry proteomics data have been
deposited to the ProteomeXchange Consortium via the PRIDE [17] partner repository with
the dataset identifier PXD005229.
Correlation analysis and development of a high dimensional model
As peptide profiles across the samples were not normally distributed, a correlation analysis
was performed for peptide discovery using the non-parametric Spearman’s rank coefficient to
estimate the correlation of individual peptides using age as a continuous variable. All peptides
present in the full cohort were included in the correlation analysis since a frequency threshold
was not set. The statistical significance was assumed at p-value less than 0.05. The p-value was
adjusted by applying Benjamini-Hochberg [18] using an R-based statistical software (version
2.15.3). Generation of Box-Whisker plots and the Mann-Whitney test were performed and
verified with MedCalc version 8.2.1.0 (MedCalc Software, Mariakerke, Belgium). MosaCluster
(version 1.7.0) was used to build a classifier based on support vector machine (SVM) that
allows the classification of samples in the high dimensional data space [19,20]. MosaCluster
calculated classification scores based on the amplitudes of ageing peptides. Classification is
performed by determining the Euclidian distance (defined as the SVM classification score) of
the vector to a maximal margin hyperplane. The SVM-classifier uses the log transformed
intensities of x features (peptides) as coordinates in an x-dimensional space. It then builds an
x-1 dimensional hyperplane that spans this space by performing a quadratic programming
optimisation of a Lagrangian using the training labels only while allowing for samples to lie on
the wrong side of the plane. For such mistakes in classification the SVM introduces a cost
parameter C. Because non separable problems in low dimensions may be separable in higher
dimensions, the SVM uses the so called Kernel-trick to transform the samples to a higher
dimensional space. MosaCluster uses the standard radial basis functions as kernel. These
functions are just Gaussians with the parameter gamma controlling their width. There are
generally implemented in SVMs in all popular data mining software, particularly the kernlab
cran contributed R package is a versatile tool for building SVM based-classifiers [21]. After
Proteomic analysis in mouse ageing
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identification of significant biomarkers and generation of different classifiers, they were
assessed in a test set or a validation set to check their performance.
Orthology
Orthology between age-correlated mouse and human peptides was defined as follows: i) iden-
tical fragments, ii) peptides derived from the same protein region with a minimum overlap of
6 amino acids between the two species and iii) peptide sequences with a one amino acid gap
[22]. In addition only peptides with the same correlation direction with age in mice and
humans were retained.
Results
Identification of age-correlated peptides in mice
To identify peptides associated with ageing, the urinary proteome profiles of a cohort of 89
C57BL/6 wild-type mice were analysed by CE-MS (Fig 1). A correlation analysis of individ-
ual peptides with age was performed using age as a continuous variable and 295 peptides
were significantly correlated with age (p 0.05) (S1 Table). A considerable number of pep-
tides (42%) associated to mouse ageing were fragments of different collagen proteins, simi-
larly to what was observed in human ageing [7,8]. Additionally, some age-correlated
peptides were only identified in mice including fragments of kidney androgen-regulated pro-
tein, complement factor D and pro-epidermal growth factor (S1 Table). Non collagen pep-
tides were predominantly positively correlated with age and included fragments of kidney
androgen-regulated protein, pro-epidermal growth factor, alpha-1-antitrypsin, major uri-
nary protein, meprin A subunit alpha, complement factor D, uromodulin and serine prote-
ase inhibitor A3K whereas collagen fragments were predominantly negatively correlated
with age and included collagen alpha-1(I) chain, collagen alpha-1(III) chain and collagen
alpha-2(I) chain (S1 Table, see rho factor). The two most strongly negatively age-correlated
peptides were collagen alpha-1(III) chain and collagen alpha-1(I) chain fragments (respec-
tively ρ = -0.787, p< 0.0001 and ρ = -0.739, p< 0.0001 Table 1) whereas the two most
strongly positively correlated peptides corresponded to E3 ubiquitin-protein ligase and a
kidney androgen-regulated protein fragments (respectively, ρ = 0.717, p< 0.0001 and ρ =
0.709, p< 0.0001 respectively Table 1).
Assessment of urinary proteome similarity in wild-type mice and humans
ageing: Individual peptides
We have recently identified urinary peptides related to human ageing [7]. Briefly, the urinary
proteome of 1227 healthy individuals between (20–86 years old) was analysed and correlated
with age. A total of 116 peptides predominantly made up of different collagen fragments (72%)
were found to be associated to apparent healthy human ageing [7]. Collagen fragments were
predominantly negatively correlated and comprised mainly collagen alpha-1(I) chain, collagen
alpha-1(III) chain, and collagen alpha-2(I) chain whereas non collagen fragments were pre-
dominantly positively correlated and comprised for example fibrinogen fragments and
uromodulin.
Since collagen fragments and uromodulin fragments were observed to be associated to both
mouse and human ageing and represented the majority of the peptides, they were further used
to evaluate the similarity between mouse and human ageing based on orthology analysis. Forty
nine unique sequences in mice showed orthology to 42 unique sequences in humans, although
1 peptide in mice could have several corresponding ortholog peptides in humans and vice
Proteomic analysis in mouse ageing
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versa (Table 2, S2 Table). Ortholog sequences included collagen alpha-1(I) chain, collagen
alpha-1(III) chain, collagen alpha-2(I) chain and uromodulin. Proteome profiles of the ortho-
log peptides in young and old wild-type mice and healthy subjects were depicted for visual
representation. The decreased of collagen alpha-1(I) (respectively Figs 2 and 3, green stars)
and the increased of uromodulin peptides (respectively Figs 2 and 3, red stars) with age were
depicted. Overall, of the 295 peptides associated to mouse ageing, 49 displayed similarity with
urinary peptides of human ageing in healthy individuals.
Fig 1. Summary of the study design. The human study has already been published [5]. The orthology analysis enabled to identify 49
ortholog peptides in mice, equivalent to 42 peptides in humans. Then ageing models were generated using ortholog peptides in mice and
humans. ACM49: ageing classifier in mouse containing 49 peptides, ACH42: ageing classifier in human containing 42 peptides.
doi:10.1371/journal.pone.0166875.g001
Proteomic analysis in mouse ageing
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Assessment of urinary proteome similarity in wild-type mice and humans
ageing: Use of multidimensional peptide models
To further investigate whether the mouse urinary peptides were representative of human age-
ing, we developed multidimensional classifiers based on the ortholog peptides. We scored
mice and human age using these classifiers based on the hypothesis that correct age classifica-
tion by these ortholog peptides in both mice and humans validates the translatability of the
mouse peptides. With this aim, an ageing classifier was developed, using the 49 ortholog age-
correlated mouse peptides, along with a training cohort of wild-type mice (N = 39) using sup-
port vector machine (SVM)-based modelling. This resulted in the classifier called ACM49
(ACM: ageing classifier in mouse). To validate the classifier, a cohort of 45 wild-type mice
including young (12 weeks; N = 15), mature (48 weeks; N = 15), and old (96 weeks; N = 15)
were used. In this validation, the ACM49 classifier was able to discriminate between the differ-
ent age groups with p< 0.0001 in young versus old; p = 0.0030 in young versus mature; and
p = 0.0045 in mature versus old. As depicted in the Box-Whisker plot (Fig 4), the median
scores from the ACM49 classifier increased proportionally to the age of wild-type mice. Addi-
tionally, ACM49 was also used to assess the age of telomerase knock out mice samples (N = 5).
Findings revealed that classification scores of 61 weeks old telomerase knock out mice were
significantly higher (p = 0.0019) than of 96 weeks old wild-type mice (Fig 4).
The same peptides, but now ortholog in humans, comprised of 42 peptides (S2 Table) were
modelled in a classifier called ACH42 (ACH: ageing classifier in human) using a training
human cohort of healthy subjects (N = 50). To validate the classifier, an independent cohort of
60 healthy subjects including young (20–39 years; N = 20), mature (40–59 years; N = 20) and
old (60 years and over; N = 20) were used. In this independent validation the ACH42 classifier
Table 1. The 20 best age-correlated peptides identified in mice.
Rho factor Adjusted p-value Sequence Protein name Start AA Stop AA
-0.787 3.08E-16 GSPGAKGEVGpAGSPGSNGSPGQRGEpGpQ Collagen alpha-1(III) chain 344 373
-0.739 2.50E-13 GQpGAKGEpGDTGVKGDAGPpGP Collagen alpha-1(I) chain 810 832
-0.680 9.48E-11 GQPGAKGEpGDTGVKGDAGPpGP Collagen alpha-1(I) chain 810 832
-0.678 1.10E-10 ppGpAGAAGPAGNPGADGQpGAKG Collagen alpha-1(I) chain 364 387
-0.620 2.14E-08 GLPGppGPpGEGGKQGDQ Collagen alpha-1(I) chain 531 547
-0.582 3.34E-7 GLPGppGPpGEGGKQGDQ Collagen alpha-1(II) chain 666 683
-0.577 4.5E-07 YKGmVGSIGAAGpPGEEGPRGppGEAG Collagen alpha-2(IX) chain 250 276
-0.553 1.73E-06 DEAGSEAHREGETR Fibrinogen alpha chain 527 540
-0.551 1.94E-06 KGTAGEpGKAG Collagen alpha-1(I) chain 575 585
-05.47 2.51E-06 AGPpGPTGPTGPp Collagen alpha-1(I) chain 320 332
0.543 2.98E-06 SLNEKLQN Coiled-coil domain-containing protein 18 1069 1076
0.560 1.15E-06 ELQNSIIDLLNS Kidney androgen-regulated protein 30 41
0.564 9.15E-7 VSINKELQNSII Kidney androgen-regulated protein 25 36
0.572 5.99E-7 LVSINKELQNSIIDLLNS Kidney androgen-regulated protein 24 41
0.597 1.15E-07 SINKELQNSIIDLLNS Kidney androgen-regulated protein 26 41
0.599 1.07E-7 AAPEIILGNPV Triple functional domain protein 2962 2972
0.694 2.54E-11 LVSINKELQNS Kidney androgen-regulated protein 24 34
0.697 1.92E-11 EEHTQSPIFLGKVVDPTHK Alpha-1-antitrypsin 1–1 395 413
0.709 6.35E-12 VSINKELQNS Kidney androgen-regulated protein 25 34
0.717 3.00E-12 MPSLVVVSGGNSLNNLI E3 ubiquitin-protein ligase HERC2 2846 2862
In bold are negatively correlated peptides and positively correlated peptides are in italic. p = hydroxylated proline.
doi:10.1371/journal.pone.0166875.t001
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Table 2. Ortholog peptides identified in mice and humans.
Peptide ID
mice
Sequence mice Peptide ID
humans
Sequence humans Gene
symbol
1504650 GPpGKNGDDGEAGKpGRpGERGPpGP 68411 PpGPpGKNGDDGEAGKpGRp COL1A1
16415 KNGDDGEAGKpGRpG 41476 GPPGkNGDDGEAGKPG COL1A1
1504057 KNGDDGEAGKpGRpGERGPpGP1 102819 GPpGKNGDDGEAGKPGRpGERGPpGpQ COL1A1
1504810 KNGDDGEAGKpGRPGERGpPGP 38011 PpGKNGDDGEAGKpG COL1A1
19556 GEAGKPGRpGERGPpGP2 93897 PpGKNGDDGEAGKPGRpGERGppGP COL1A1
19556 GEAGKPGRpGERGPpGP2 99919 PpGKNGDDGEAGKPGRpGERGppGPQ COL1A1
6931 GRpGERGPpGP 87365 KNGDDGEAGKpGRpGERGPPGpQ COL1A1
1504057 KNGDDGEAGKpGRpGERGPpGP1 89642 KNGDDGEAGKPGRpGERGPPGpQG COL1A1
7545 AGPpGPTGPTGPp3 141007 ARGNDGATGAAGPpGPTGPAGppGFpGAVGAKGEAGPQGPRG COL1A1
7545 AGPpGPTGPTGPp3 155132 ARGNDGATGAAGpPGPTGPAGPPGFpGAVGAKGEAGpQGpRGSEGPQG COL1A1
37057 NSGEpGApGNKGDTGAKGEpGATGVQGPpGP 50172 ApGSKGDTGAKGEpGPVG COL1A1
18625 TGSpGSPGPDGKTGPpGP 29538 SpGSPGPDGKTGPp COL1A1
18875 TGSpGSpGPDGKTGPpGP 46649 SpGSPGPDGKTGPpGPAG7 COL1A1
20909 TGSpGSPGPDGKTGPpGPAG 46649 SpGSPGPDGKTGPpGPAG7 COL1A1
16583 GSpGSPGPDGKTGPpGP 29538 SpGSPGPDGKTGPp8 COL1A1
16886 GSpGSpGPDGKTGPpGP 29538 SpGSPGPDGKTGPp8 COL1A1
19345 GSpGSpGPDGKTGPpGPAG 46649 SpGSPGPDGKTGPpGPAG7 COL1A1
18066 SpGSPGPDGKTGPpGPAG 46649 SpGSPGPDGKTGPpGPAG7 COL1A1
3902 KGTAGEpGKAG 117371 VMGFPGpKGAAGEPGKAGERGVpGppGAVGPAG COL1A1
1506170 TAGEpGKAGERGLpGPpG4 122825 GEpGKAGERGVpGPPGAVGpAGKDGEAGAQGPPGP COL1A1
1506170 TAGEpGKAGERGLpGPpG4 127351 AAGEPGkAGERGVpGPpGAVGPAGKDGEAGAQGPPGP COL1A1
1505741 ERGEQGPAGSpG 135166 ERGEQGPAGSpGFQGLpGPAGPpGEAGKpGEQGVPGD COL1A1
19814 GLPGpAGPpGEAGKpGEQ 100255 GLPGpAGppGEAGKPGEQGVPGDLGApGP9 COL1A1
4170 KpGEQGVPGD 100255 GLPGpAGppGEAGKPGEQGVPGDLGApGP9 COL1A1
17232 KpGEQGVpGDLGApGP 100255 GLPGpAGppGEAGKPGEQGVPGDLGApGP9 COL1A1
16079 GQPGAKGEpGDTGVKG 92841 ADGQPGAKGEpGDAGAKGDAGPpGPAGP10 COL1A1
26939 GQPGAKGEpGDTGVKGDAGPpGP 121241 ADGQPGAKGEpGDAGAKGDAGPpGPAGPAGPPGPIG COL1A1
27161 GQpGAKGEpGDTGVKGDAGPpGP 28850 DGQPGAKGEpGDAG COL1A1
27388 GQpGAKGEpGDTGVKGDAGppGP 40344 DGQPGAKGEPGDAGAK COL1A1
9877 PGAKGEpGDTGVK 44802 DGQPGAKGEpGDAGAKG COL1A1
14420 PGAKGEpGDTGVKGD 92841 ADGQPGAKGEpGDAGAKGDAGPpGPAGP10 COL1A1
24239 ETGPAGRpGEVGPpGPpGPAG 140803 ETGPAGRpGEVGPpGpPGPAGEKGSPGADGPAGAPGTPGPQG11 COL1A1
20667 GEVGPpGPpGpAGEKGSpG 140803 ETGPAGRpGEVGPpGpPGPAGEKGSPGADGPAGAPGTPGPQG11 COL1A1
38376 ESGREGSpGAEGSpGRDGApGAKGDRGETGP 127432 GPpGESGREGAPGAEGSpGRDGSpGAKGDRGETGp COL1A1
35125 REGSpGAEGSpGRDGApGAKGDRGETGP5 130077 GPpGESGREGApGAEGSpGRDGSpGAKGDRGETGPA COL1A1
35125 REGSpGAEGSpGRDGApGAKGDRGETGP5 51175 EGSpGRDGSpGAKGDRG COL1A1
10361 DGApGAKGDRGET 124886 PpGESGREGAPGAEGSpGRDGSpGAKGDRGETGP COL1A1
17249 pGPVGPAGKNGDRGET 128435 DRGETGPAGPpGApGAPGAPGPVGpAGKSGDRGETGP COL1A1
25169 QGIpGTGGPpGENGKpGEpGP 16910 GLpGTGGPpGENGKPGEPGp COL3A1
15377 GIpGTGGPpGENGKpG 61304 GLpGTGGPpGENGKpGEPGpKG12 COL3A1
12858 GPpGENGKpGEpGP 61304 GLpGTGGPpGENGKpGEPGpKG12 COL3A1
31210 QNGEpGAKGERGApGEKGEGGPpGP 70911 GAPGQNGEPGGkGERGApGEKGEGGPpG COL3A1
27744 GEpGAKGERGApGEKGEGGPpGP 97638 ApGEKGEGGPpG13 COL3A1
8738 ApGEKGEGGPpGP 97638 ApGEKGEGGPpG13 COL3A1
1505438 ApGLpGPRGIpGPAG 126318 TGAkGAAGLpGVAGApGLpGPRGIpGPVGAAGATGARG COL1A2
1506234 KGEQGpAGPPGFQGLpG 138279 EVGKpGERGLHGEFGLpGpAGpRGERGPPGESGAAGP COL1A2
(Continued )
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was able to discriminate between the different age groups with p = 0.0005 in young vs old;
p< 0.0001 in young vs mature; and p = 0.0453 in mature vs old. The classifier was significantly
able to discriminate between different age groups as younger subjects had a lower median
score generated by the ACH42 classifier which progressively increased with age (Fig 5). The
data suggested that urinary peptide classifiers exclusively comprising ortholog peptides, can
discriminate the age in both species.
Table 2. (Continued)
Peptide ID
mice
Sequence mice Peptide ID
humans
Sequence humans Gene
symbol
30714 SGTTGEVGKpGERGLpGEFGLpGP 148645 EVGKpGERGLHGEFGLPGPAGpRGERGpPGESGAAGPTGPIG COL1A2
27017 DGPpGRDGQpGHKGERGYpG6 112515 GRDGNpGNDGPpGRDGQpGHKGERGYpG COL1A2
27017 DGPpGRDGQpGHKGERGYpG6 80306 NDGPpGRDGQpGHKGERGYpG COL1A2
36597 PGKDGEVGPSGPVGPPGLAGERGEQGppGP 113351 GpSGpVGpPGLAGERGEQGPpGPTGFQGLPG COL5A2
25768 SGNFIDQTRVLNLGPITR 53181 SGSVIDQSRVLNLGPI UMOD
6864 FIDQTRVLN 43605 SVIDQSRVLNLGPI UMOD
18643 IDQTRVLNLGPITR 50056 SVIDQSRVLNLGPIT14 UMOD
16362 DQTRVLNLGPITR 50056 SVIDQSRVLNLGPIT14 UMOD
3736 VLNLGPITR 50056 SVIDQSRVLNLGPIT14 UMOD
The superscripted numbers represent sequences that have several ortholog in either mice or humans. In bold are the ortholog sequences. p = hydroxylated
proline.
doi:10.1371/journal.pone.0166875.t002
Fig 2. Abundance of ortholog peptides in wild-type mice. (A) Young mice (4 weeks old) and (B) wild-type old mice (84 weeks old). The green stars
represent collagen alpha-1(I) chain peptides where as the red stars represent uromodulin peptides.
doi:10.1371/journal.pone.0166875.g002
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Discussion
The urinary proteome profiles of 89 wild-type mice were analysed and compared with the pro-
teome profiles of a unique cohort of 1227 healthy subjects to evaluate the translatability of age-
ing findings from mice to humans.
Using urinary proteomics, common molecular mechanisms describing ageing in human
and mouse were identified. The difference in the number of identified peptides (295 versus
116) between mice and humans most likely lies in the high genetic variability in humans and
their exposure to environmental changes leading to age-dependent changes being obstructed.
Therefore, the great biological variance resulted in a lower number of biomarkers. In both spe-
cies, a decrease in collagen fragments and increase in uromodulin peptides were identified as
key molecular changes observed during ageing. These ortholog peptides which predominantly
included collagens fragments were able to discriminate among different age groups in both
human and mouse cohorts. These findings not only highlight the translatability from mice to
humans, but also specifically point out that this translatability is mostly attributed to collagens.
Thus, findings highlight the key role of collagens in human and mouse ageing processes.
Indeed, the pivotal role of collagens in ageing has previously been shown [3,7,8]. However,
the strong homology in mouse and human collagens in ageing via investigation of the urinary
proteome has not been shown before. This observation suggests that mice can be used to assess
anti-ageing interventions targeting collagens [23] in humans. As a disturbance in the collagen
homeostasis is associated with several chronic age-related conditions including cancers [24],
chronic kidney diseases (CKD) [25] and cardiovascular diseases [26], mice can also be used
to develop therapeutic interventions for humans against these age-associated pathologies.
Fig 3. Abundance of ortholog peptides in healthy subjects. (A) Young subjects (20–39 years old) and (B) healthy old subjects in (60 years old and
over). The green stars represent collagen alpha-1(I) chain peptides where as the red stars represent uromodulin peptides.
doi:10.1371/journal.pone.0166875.g003
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Furthermore, the identification of age-correlated ortholog peptides enables to gain
increased insight into molecular mechanisms involved during human and mouse ageing. In
humans, ageing was characterised by the decrease of fibrillary collagen fragments, especially
collagen alpha-1(I) chain, collagen alpha-1(III) chain and collagen alpha-2(I) chain. The
reduction in collagen type I and type III synthesis has previously been associated to skin ageing
[27] and to systemic ageing [7,8]. Indeed, a reduction in collagen synthesis may indicate a per-
turbation in the extracellular matrix (ECM) remodelling. The ECM is ubiquitous in the organ-
ism and plays a pivotal role in tissue elasticity and integrity [28]. Perturbations of the ECM
have been associated with several pathologies [28]. For instance, perturbations in the ECM
have been shown to cause fibrosis; a condition characterised by an abnormal accumulation of
ECM components. Fibrosis has been associated with renal diseases, cardiovascular diseases
and cancers [29]. Hence in humans, ageing is characterised by a perturbation in collagen
homeostasis which can lead to fibrosis formation followed by a myriad of age-related
complications.
In mice, the urinary excretion of fibrillar type I and III collagen fragments representing the
majority of collagenous peptides decreased with increasing age. This may be reflective of
Fig 4. Box-whisker plot depicting the age classification in wild-type and telomerase knock-out mice. * Statistically significant p-value, WT:
wild-type, Terc-/-: telomerase knock-out mice and w: weeks.
doi:10.1371/journal.pone.0166875.g004
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increased cross-linking and subsequently increased collagen biosynthesis and decreased activ-
ity of matrix metalloproteinases and other collagen degrading enzymes [30]. In a recent study,
a mouse model developing resistance to type I collagenase activity (Col1a1r/r) was demon-
strated to promote premature ageing [31]. The Col1a1r/r mice were shown to have shortened
lifespan in comparison to WT mice and they developed hypertension caused by aortic stiffness.
Interestingly, collagenase-resistant collagen was reported to promote premature ageing by
inducing senescence in vascular smooth muscle cells due to inadequate communication with
αvβ3 integrin [31]. Moreover, a type III collagen-deficient mouse was generated to assess blad-
der function [32]. It was shown in this study that deficiency in type III collagen fragment
caused reduced tension or elasticity subsequently resulting in impaired bladder contraction
and development [32]. In humans, resistance in collagen degradation by collagenases has been
previously shown to predict the chronological age using diaphragm tissues obtained from
biopsies [33]. In addition to collagen fragments, uromodulin was shown to increase with age.
Uromodulin is a protein exclusively produced in the kidney and the most abundant protein in
urine. Its biological function still remains unknown however; deregulation in its synthesis has
been reported to be associated with hypertension and chronic kidney diseases [34].
Fig 5. Box-whisker plot depicting the age classification in healthy subjects. Young subjects are between 20–39 years, mature subjects are
between 40–59 years and old subjects are 60 years old and over. * Statistically significant p-value.
doi:10.1371/journal.pone.0166875.g005
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Ageing classifiers were established based on ortholog peptides and these classifiers could
discriminate the age in both humans and wild-type mice. Hence, these findings demonstrate
the translatability of results from mouse to human based on urinary proteome analysis. Similar
observations were also made while using urinary proteome analysis to compare between rat
and human in a previous study [35]. It was observed that the ZDF rat model for type 2 diabetes
mellitus displayed similarity to human cardiovascular diseases rather than chronic kidney dis-
eases based on ortholog peptides [35]. Furthermore, the mouse ageing classifier ACM49 was
able to discriminate the age in wild-type mice and also the internal age in telomerase knock-
out (Terc-/-) mouse models characterised by a short lifespan. The ACM49 revealed a discrep-
ancy between the chronological age of Terc-/- and their internal age as the 61 weeks old Terc-/-
mouse models had higher scores compared to 96 weeks WT mice. Though findings in mice
are translatable in humans when focusing on ortholog peptides, this observation cannot be
generalised to all identified age-related peptides. Indeed looking at the differences in the num-
ber of identified peptides, and also looking at the unique peptides specific to each species, it is
obvious that findings using mouse models must be interpreted with care.
In conclusion, we have demonstrated that mice can be good models to study human ageing
when focusing on ortholog peptides. One major advantage of using urinary proteomics to
study ageing, as suggested by the results, is the ability to obtain a representative readout of
human ageing using mouse models, hence, allowing eventually to investigate interventions in
the management of ageing-associated complications.
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